BTIG Keeps Their Hold Rating on Dexcom


In a report released yesterday, Sean Lavin from BTIG maintained a Hold rating on Dexcom (NASDAQ: DXCM). The company’s shares closed yesterday at $74.31, close to its 52-week high of $79.31.

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 14.9% and a 63.0% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Varian Medical Systems.

Dexcom has an analyst consensus of Moderate Buy, with a price target consensus of $73.63.

Find more picks by Best Performing Analysts >>

The company has a one-year high of $79.31 and a one-year low of $42.62. Currently, Dexcom has an average volume of 1.12M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps. The company was founded by John F.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts